In 2014, Hinsinger et al. found that the levels of CHI3L1 in the CSF and the serum were higher in RRMS patients than in CIS, while CSF CHI3L2 levels were lower in RRMS than in progressive MS. Here, CHI3L1 is linked to in situ carcinoma.